Sacituzumab tirumotecan clinical trials
Also written SKB264 and MK-2870.
How each study uses sacituzumab tirumotecan is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the sacituzumab tirumotecan studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
106 studies that test it; most in 2026 (44); 7 more planned to start later
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2022 | 4 |
| 2023 | 9 |
| 2024 | 16 |
| 2025 | 32 |
| 2026 | 44 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 50 · Other 63
Merck Sharp & Dohme LLC (29) · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (17) · Tianjin Medical University Cancer Institute and Hospital (8) · Fudan University (6) · Klus Pharma Inc. (3) · Latin American Cooperative Oncology Group (3) · National Cancer Center, Japan (3) · M.D. Anderson Cancer Center (2)
Often tested with
Tested in the same studies.
Tagitanlimab (6) · Anlotinib (5) · Anti-PD-1/Anti-VEGF-A Bispecific Antibody CR-001 (3) · Paclitaxel (2) · Patritumab deruxtecan (2) · Enfortumab vedotin (1) · Prednisone (1) · Prednisolone (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 1 phase 3 study under way
Sacituzumab tirumotecan is the comparator. A study of two new drugs counts under both.
- 1Ruzaltatug rezetecan · Suzhou Suncadia Biopharmaceuticals Co., Ltd. · next primary completion Dec 2028
Reaching primary completion within a year · 27, 8 in phase 3
Studies that test sacituzumab tirumotecan, phase 3 first.
- Nov 2026A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung CancerPhase 3 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Dec 2026A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerPhase 3 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Dec 2026Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast CancerPhase 3 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Apr 2027A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast CancerPhase 3 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- May 2027A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerPhase 3 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- May 2027Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)Phase 3 · Merck Sharp & Dohme LLC
- Jul 2027A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine TherapyPhase 3 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Jul 2027A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)Phase 3 · Merck Sharp & Dohme LLC
- Dec 2026SKB264 Monotherapy in Selected Subjects With Advanced Solid TumorsPhase 2 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Dec 2026A Single-center, Phase II Clinical Trial Evaluating the Efficacy of Sacituzumab Tirumotecan in Combination With Tagitanlimab as Neoadjuvant Therapy for PD-L1-positive, Resectable Stage II to IIIB Non-small Cell Lung Cancer (NSCLC)Phase 2 · Henan Cancer Hospital
Studies
Open first, then newest update. How each study uses sacituzumab tirumotecan is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 113
- Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]RecruitingPhase 3Merck Sharp & Dohme LLCNCT06422143Written as sac-TMT
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06841354Written as Sacituzumab tirumotecan
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06966700Written as Sacituzumab tirumotecan
- A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06824467Written as Sacituzumab tirumotecan
- A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06952504Written as Sacituzumab Tirumotecan
- A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07216703Written as Sacituzumab Tirumotecan
- A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07419295Written as Sacituzumab tirumotecan
- A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07318558Written as Sacituzumab tirumotecan
- A Single-Arm Phase II Clinical Study of Sacituzumab Tirumotecan Combined With a PD-1 Inhibitor as Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma After Failure of or Progression on ImmunotherapyNot yet recruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07939204Written as Sacituzumab Tirumotecan
- A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07829783Written as Sac-TMT
- Sac-TMT in Vaginal and Vulvar CancersNot yet recruitingPhase 2Latin American Cooperative Oncology GroupNCT07804966Written as Sacituzumab Tirumotecan (sac-TMT)
- Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT06469944Written as Sacituzumab Tirumotecan (sac-TMT)
- Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT06780111Written as Sacituzumab tirumotecan
- A Phase II Investigator-initiated Trial of Sacituzumab Tirumotecan Plus Pembrolizumab in Patients With Recurrent ovarIan Clear Cell Carcinoma Previously Treated With Platinum-based Chemotherapy(NCCH2407/MK014)Not yet recruitingPhase 2National Cancer Center, JapanNCT07913568Written as Sacituzumab Tirumotecan (SKB264) plus Pembrolizumab
- Sac-TMT in Salivary Gland CancersNot yet recruitingPhase 2Latin American Cooperative Oncology GroupNCT07928193Written as Sacituzumab Tirumotecan (Sac-TMT)
- A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06312137Written as Sacituzumab tirumotecan
- Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovarian Clear Cell CancerRecruitingPhase 2Tufts Medical CenterNCT07718854Written as Sacituzumab tirumotecan
- KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)RecruitingPhase 2Merck Sharp & Dohme LLCNCT07252739Written as Sacituzumab tirumotecan (sac-TMT)
- Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06393374Written as Sacituzumab tirumotecan
- Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06170788Written as Sacituzumab tirumotecan
See all 113 studies that test sacituzumab tirumotecan →
Given beside what is tested · 5 — sacituzumab tirumotecan is usual care or a partner of the new treatment
- A Clinical Trial of MK-2010 With Sacituzumab Tirumotecan (Sac-TMT) in Participants With Solid Tumors (MK-2010)RecruitingPhase 2Merck Sharp & Dohme LLCNCT07785609Written as Sacituzumab tirumotecan
- A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT07286149Written as Sacituzumab tirumotecan
- GB268 Monotherapy or Combination Therapy for Locally Advanced/Metastatic Breast Cancer (Phase Ib/Ⅱ)Not yet recruitingPhase 1/2Eddingpharm (Zhuhai) Co., Ltd.NCT07738341Written as Sacituzumab Tirumotecan
- SKB264 Plus QL1706 in Recurrent or Metastatic Cervical CancerRecruitingPhase 2Fujian Cancer HospitalNCT07256236Written as Sacituzumab tirumotecan
- Study of Multi-mode Thermal Therapy Combined With Immunotherapy In Patients With HER2-negative Breast Cancer With Liver MetastasesNot yet recruitingPhase 2Fudan UniversityNCT07466927Written as SKB264
As the comparator · 1 — what is tested is compared with sacituzumab tirumotecan
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting1
Newly registered5
- A Single-Arm Phase II Clinical Study of Sacituzumab Tirumotecan Combined With a PD-1 Inhibitor as Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma After Failure of or Progression on ImmunotherapyNov 16, 2026NCT07939204
- Sac-TMT in Salivary Gland CancersNov 10, 2026NCT07928193
- A Phase II Investigator-initiated Trial of Sacituzumab Tirumotecan Plus Pembrolizumab in Patients With Recurrent ovarIan Clear Cell Carcinoma Previously Treated With Platinum-based Chemotherapy(NCCH2407/MK014)Nov 3, 2026NCT07913568
- MK-2870-U01 Substudy 1: A Clinical Trial of Sacituzumab Tirumotecan to Treat Prostate Cancer (MK-2870-01A)Nov 2, 2026NCT07908524
- Sacituzumab Tirumotecan Plus Toripalimab for Advanced Penile Cancer After Platinum ChemotherapyOct 30, 2026NCT07907861
Codes
What other systems call sacituzumab tirumotecan · ClinicalTrials.gg INT014653
- UNII (FDA) 3DV5TD1VL3SACITUZUMAB TIRUMOTECANOne source FDA
- NCI Thesaurus C166409Sacituzumab TirumotecanOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 3DV5TD1VL3 | SACITUZUMAB TIRUMOTECAN | One source FDA |
| NCI Thesaurus | C166409 | Sacituzumab Tirumotecan | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.